Chapter 320 - Molecular targeted therapy

Question 1

Which is the most common adverse event associated with Toceranib in dogs?
a) Renal toxicity
b) Gastrointestinal toxicosis
c) Hepatotoxicity
d) Hypothyroidism

Answer 1

b) Gastrointestinal toxicosis

Question 2

In a study of dogs with mast cell tumours treated with toceranib, what was the response rate for c-KIT mutation-positive tumours?
a) 25%
b) 37%
c) 69%
d) 50%

Answer 2

c) 69%

37% for c-KIT mutation negative tumours

Question 3

What is the primary direct action of Toceranib?
a) Inhibition of KIT
b) Inhibition of vascular endothelial growth factor receptor 2 (VEGFR2)
c) Inhibition of platelet-derived growth factor receptor (PDGFR) beta
d) Inhibits the function of exportin1 (XPO1)

Answer 3

a) Inhibition of KIT

Question 4

What are the two tumours that respond to the direct action of toceranib in dogs
a) Mast cell tumours and adenocarcinomas
b) Mast cell tumours and osteosarcomas
c) Mast cell tumours and GI stromal tumours
d) Mast cell tumours and chemodectomas

Answer 4

c) Mast cell tumours and GI stromal tumours

Question 5

Verdinexor a selective nuclear export inhibitor has been demonstrated as tolerable and effective in treatment of which canine neoplasm?
a. Lymphoma
b. Adenocarcinoma
c. Squamous cell carcinoma
d. Melanoma

Answer 5

a. Lymphoma